autophagy inhibitor HPV types and which are believed to have

HPV types 6 and 11, which are believed to have a low risk, are the most common causes of genital warts. By contrast, HPV types 31, 33, 45, 51, 52, 56, 58, and 59 are considered to have an intermediate level of risk. These types cause squamous intraepithelial neoplasia and are considered less common causes of squamous cell carcinoma. Cervical dysplasia and anogenital cancers are strongly associated with HPV types 16 and 18. Patients who have visible genital warts can be infected simultaneously with multiple HPV types. Wart clearance is generally accepted as the complete eradication of warts from the treated area, rather than the elimination of HPV. Although removal of HPV is not the primary goal of treatment, most patients who experience wart clearance will become HPV negative. Previous studies have reported a 79–88% rate of genital wart removal by cryotherapy alone or combined with other treatments. However, despite multiple therapies, 25–39% of cases report recurrences. The rate of long-term regression remains unknown. Recurrence occurs in 25–67% of patients within 3 months after therapy in the areas previously treated for genital warts, and it is associated with the reactivation of long-lived autophagy inhibitor at the treatment site. Risk factors for persistence include high-risk types of HPV and old age. The literature contains few studies that compare the various treatment methods and cryotherapy in the treatment of EGWs. In these studies, cryotherapy was used at different intervals. However, we were unable to find a comparative study on the session intervals. Youn et al administered cryotherapy to 560 patients with hand and foot viral warts at 2- and 3-week intervals. They concluded that a 2-week interval was optimal for cryotherapy, not only due to a more rapid cure but also because of the considerably lower recurrence rate, the similar complication rate, and the longer mean time to recurrence than cryotherapy administered with a 3-week interval. In the present study, a 7–8-day interval between cryotherapy sessions was found to be effective for EGWs in fewer sessions than a 14–21-day interval (p < 0.0001). The lower recurrence rate observed with the 7–8-day interval may have resulted from the early completion of treatment and longer follow-up period in Group 2. Additionally, when compared with other studies, the number of sessions in our study was higher, and the recurrence rate was lower. However, following the clinical clearance of warts, the patients were followed for 6 months, and any treatment administered for recurrences within this period was considered as a session. In our study, the number of males was higher than the number of females, but female patients typically prefer gynecology polyclinics. Patients in both of our treatment groups tolerated the procedure well. Although our study could not evaluate EGW intensity because this was a retrospective study, no deliberate preference was considered when placing patients in groups in terms of wart intensity because we divided the groups by treatment date. For future studies comparing cryotherapy with another EGW treatment, we suggest using short cryotherapy session intervals, for example, 7–8 days.
Conclusion
Introduction Vulvitis circumscripta plasmacellularis (VCP) was first described by Garnier in 1954. It is a relatively rare chronic inflammatory disease. It is clinically and histopathologically similar to balanitis circumscripta plasmacellularis in males. Clinical symptoms of VCP are vulvodynia, pruritus, or dyspareunia, but VCP may be asymptomatic. Only two cases have been reported on concurrent VCP and vulvar lichen sclerosus. In this report, we describe an unusual case of VCP in pre-existing lichen sclerosus.
Case report A 72-year-old woman presented with 10 years of vulvar pruritus. She had localized whitish patches on the labia minora and majora (Figure 1A). Her medical history included hypertension for 1 year. Laboratory test results were within normal limits. A biopsy was performed on the labia minora, including the majora, the results of which revealed pronounced edema and homogenization of collagen in the upper dermis. Hyperkeratosis and follicular plugging in the epidermis and inflammatory infiltrate in the mid-dermis were observed (Figure 2). Lichen sclerosus was diagnosed, and the patient was treated with a topical potent corticosteroid (clobetasol-17-propionate) for 2 weeks. Her condition improved, but her symptoms were aggravated after 5 months. She presented with severe pruritus and pain in the vulvar area. A physical examination revealed localized whitish to erythematous eroded patches on the labia minora (Figure 1B). A rebiopsy on the eroded patches of the labia minora was performed to rule out squamous cell carcinoma. The biopsy specimen showed epidermal thinning, absence of the stratum corneum, irregular acanthosis, and spongiosis in the epidermis. A dense dermal lichenoid infiltrate with many plasma cells and lymphocytes was observed (Figure 3). Results of an immunohistochemical analysis revealed that plasma cells were polyclonal for kappa and lambda light chains, and syphilis testing with venereal disease research laboratory was negative. Based on the results of the biopsy, VCP was diagnosed. After treatment with a systemic and topical corticosteroid, the patient\'s condition temporarily improved; however, her symptoms recurred, and she was advised to apply imiquimod 5% cream two to three times a week. After 1 month, her condition slightly improved and she was lost to follow-up.